Bionano Symposium 2026 continues with Day 2: New Frontiers in Oncology and Bioprocessing Applications on February 24, 2026, from 7:00-10:00 AM PT. Attendees may also explore scientific posters ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

In the world of oncology drug development, the standard playbook is simple: Race to earlier lines of treatment, where patient populations are larger. But Eli Lilly is flipping that script with its ...

Please provide your email address to receive an email when new articles are posted on . Adding ianalumab to ibrutinib allowed many patients with CLL to stop daily ibrutinib for 1 to 2 years. More than ...

Jaypirca is approved for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option. The BRUIN-CLL-321 trial showed Jaypirca improved progression-free survival ...

Copyright: © 2025 The Authors. Published by Elsevier Ltd. We performed a retrospective analysis of patients with CLL registered in the Brazilian CLL Registry between ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

Pirtobrutinib significantly improved progression-free survival in treatment-naïve CLL/SLL patients compared to bendamustine and rituximab. Overall survival data shows a positive trend favoring ...

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with a wide range of clinical presentations that, over time, may or may not require treatment. While a minority of patients require ...

BOSTON--(BUSINESS WIRE)--Method AI, a medical technology company focused on improving oncology outcomes through image-guided surgical navigation, announced today it has raised $20 million in Series A ...

Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...

Senior Lecturer of Exercise Immunology, Faculty of Health and Medical Sciences, School of Biosciences, University of Surrey CLL starts when a type of immune cell called a B cell – normally responsible ...